News-Medical.Net on MSN
New data supports earlier use of evolocumab in high-risk diabetes
Adding the PCSK9 inhibitor evolocumab to a high-intensity, cholesterol-lowering regimen reduced the risk of a first major ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback